Strs Ohio Takes Position in Aldeyra Therapeutics, Inc. $ALDX

Key Points

• Strs Ohio has acquired a new stake in Aldeyra Therapeutics, purchasing 76,500 shares valued at approximately $440,000, enhancing their ownership to around 0.13% of the company.
• Shares of Aldeyra Therapeutics opened at $4.95, with a market capitalization of $296.51 million and a 1-year price range of $1.14 to $7.20.
• Recently, the stock received upgraded ratings from analysts, moving from a "sell" to a "hold" rating, with a consensus target price of $9.50, indicating potential for growth.

Strs Ohio acquired a new stake in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 76,500 shares of the biotechnology company's stock, valued at approximately $440,000. Strs Ohio owned approximately 0.13% of Aldeyra Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Capital Advisors Wealth Management LLC purchased a new position in Aldeyra Therapeutics in the first quarter valued at $62,000. Wealth Enhancement Advisory Services LLC purchased a new position in Aldeyra Therapeutics in the first quarter valued at $63,000. ProShare Advisors LLC purchased a new position in Aldeyra Therapeutics in the fourth quarter valued at $70,000. CWM LLC boosted its holdings in Aldeyra Therapeutics by 1,164.4% in the first quarter. CWM LLC now owns 19,244 shares of the biotechnology company's stock valued at $111,000 after purchasing an additional 17,722 shares during the period. Finally, Fox Run Management L.L.C. purchased a new position in Aldeyra Therapeutics in the first quarter valued at $132,000. 59.71% of the stock is owned by institutional investors and hedge funds.

Aldeyra Therapeutics Price Performance

Shares of NASDAQ ALDX opened at $4.95 on Tuesday. The company has a market capitalization of $296.51 million, a price-to-earnings ratio of -5.82 and a beta of 0.80. The business has a 50-day moving average of $5.38 and a two-hundred day moving average of $4.13. Aldeyra Therapeutics, Inc. has a 1 year low of $1.14 and a 1 year high of $7.20.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05. As a group, equities research analysts expect that Aldeyra Therapeutics, Inc. will post -0.92 earnings per share for the current year.

Insider Transactions at Aldeyra Therapeutics

In related news, insider Stephen Machatha sold 22,073 shares of the business's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $5.15, for a total value of $113,675.95. Following the transaction, the insider owned 221,799 shares in the company, valued at $1,142,264.85. The trade was a 9.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 8.50% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Wall Street Zen upgraded Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st. Zacks Research upgraded Aldeyra Therapeutics to a "hold" rating in a report on Friday, August 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $9.50.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

Want to see what other hedge funds are holding ALDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.